Novartis’ Post

As cancer treatment advances, patients and doctors push back against drugs' harsh side effects Chemotherapy is like a battering ram where aggressive strikes are a good strategy. But newer cancer drugs are more like having a front door key. They target a mutation that drives cancer cell growth, for example, or rev up the body's immune system to join the fight. #cancertreatment | #chemotherapy | #immunesystem | #cancercellgrowth | #Healthnews Read more:

Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults and a hard to treat disease. However, recent research has uncovered the role of IDH mutations in AML pathogenesis. IDH mutations can be targeted with innovative therapies like ivosidenib and enasidenib, leading to increased survival rates. Excitingly, a new triplet therapy combining ivosidenib, venetoclax, and azacytidine has shown promising results in clinical trials, improving patients outcome. Champions Oncology is committed to accelerating the development of therapeutics targeting this complex disease, offering the largest bank of well characterized AML models for your ex vivo and in vivo studies. Read our latest blog that dives into new Acute Myeloid Leukemia (AML) therapies targeting IDH1 mutations. #AML #NewTherapies #blog #TripletTherapy #ivosidenib #enasidenib #venetoclax #azacytidine #AcuteMyeloidLeukemia #IDH #OncologyResearch #CancerResearch #oncology #cancer https://hubs.li/Q02lcDgl0

"Breyanzi, a CD19-directed CAR T cell therapy, is approved for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have already received treatment with a Bruton tyrosine kinase inhibitor (BTKi) and B cell lymphoma 2 inhibitor (BCL2i)." #DahliaConsulting #BiopharmaceuticalIndustry #CommercialLifeSciences #ManagementConsultant #LifeSciencesBusinessStrategy #GlobalPharma #GlobalBioTech #SupplychainOperations #CommercialOperations #CGTcommercialization #Manufacturing #QualityAssurance #OperationalExcellence #FinancialAnalysis #OpModelDesign #LifeScience #BioTechnology #Bioprocessing #Biosimilars #BioPharmaIndustry #MedicalResearch #CDMO #GMP #GMPbatch #GMPmanufacturing #GenomeEditing #GeneTherapy #CellTherapy #Car_T #mRNA #cGMP #ClinicalGradeManufacturing #ClinicalGradeProduction #BiologicsLicenseApplication #BLA #Pharmaceuticals #RegenerativeMedicine #BioSpace #BMS #BristolMeyersSquibb #Leukemia #Breyanzi #CD19 #ChronicLymphocyticLeukemia #CLL #SmallLymphocyticLymphoma #SLL #BrutonTyrosineKinaseInhibitor #BTKi #BcellLymphoma2inhibitor #BCL2i

🚀 Exciting News：FDA APPROVEAL! 🚀 ✨ The FDA has officially approved Revumenib, a groundbreaking Menin inhibitor, for the treatment of relapsed or refractory acute leukemia! ✅ This innovative therapy targets MLL-rearranged leukemias, offering new hope for patients who have limited treatment options. Revumenib's unique mechanism of action disrupts the oncogenic signaling pathways driven by MLL fusion proteins, leading to significant clinical responses and improved outcomes. ✅ As we continue to advance our understanding of targeted therapies, Revumenib represents a significant step forward in personalized medicine for acute leukemia. 👉 For more detailed information: https://lnkd.in/gWqbcJUN 🎈 Join us in celebrating this milestone in cancer research and treatment! #CancerResearch #AcuteLeukemia #FDAApproval #Revumenib #TargetedTherapy #Oncology #HealthcareInnovation

IN8bio presents data showing INB-300 demonstrated improved selectivity to target leukemia cells while preserving healthy ones. The data support the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target. “INB-300 can selectively target leukemia cells while preserving healthy tissue. We are now conducting further optimization to improve the integration of membrane-bound IL-15 co-expression to potentially enhance both the efficacy and safety of next-generation adoptive cell therapies against a wider spectrum of cancers,” said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. “These results can potentially improve INB-300, as we advance towards IND enabling studies of our next-generation gamma-delta T cell therapies to treat cancers.” #AACR24 Read the release: https://lnkd.in/ez7dy7jC

🌟 Exciting New Mini Review Alert! 🌟   🔍 Delving into the Potential of Targeting Signal-Transducing Adaptor Protein-2 in Cancer Therapeutic Applications.   Adaptor proteins are key players in numerous intracellular signaling pathways. This review sheds light on the inhibitory peptide's role as a promising candidate for combatting prostate and lung cancers.   📝 Authors: Taiga Maemoto, Tadashi Matsuda, and more. 🔬 #SignalTransducingAdaptorProtein #SignalTransduction #EGFR #ProstateCancer #LungCancer #Peptides   Let's stay informed and empowered in the world of cancer therapeutics! 💪🚀  https://lnkd.in/eqCtvV7i Object]

🌟 Acute Lymphocytic Leukemia (ALL) Therapeutics Market: A Growing Frontier in Cancer Treatment 🌟 Unlock your exclusive PDF now!  https://lnkd.in/diy6F93E Acute Lymphocytic Leukemia Therapeutics Market size was valued at USD 3.66 Bn. in 2023 and the total revenue is expected to grow at 4.3% through 2024 to 2030, reaching nearly USD 4.91 Bn. Acute Lymphocytic Leukemia (ALL) is a fast-progressing malignancy affecting the blood and bone marrow. While it’s the most common type of cancer in children with promising cure rates, adults face more challenges in battling this disease. Advances in therapeutics, particularly Chimeric Antigen Receptor (CAR)-T cell therapy, are paving the way for innovative treatments. For a complimentary sample of the report, click here: https://lnkd.in/dfBUfirw Key drivers fueling the market growth include: 🔹 Increasing incidence of ALL 🔹 Technological innovations, like Novartis' CAR-T therapy, now FDA-approved 🔹 Rising public & private sector initiatives supporting early diagnosis & treatment 🔹 The strong presence of chemotherapy as the leading treatment, with targeted therapies gaining momentum 🌍 North America remains the dominant region due to its robust healthcare infrastructure and presence of key manufacturers. The introduction of pipeline drugs and groundbreaking therapies continues to push the boundaries of ALL treatment, offering hope for patients worldwide. As the field advances, the Acute Lymphocytic Leukemia Therapeutics Market is set to see substantial growth, making it an exciting area for investors and researchers alike. #Healthcare #Oncology #LeukemiaTherapeutics #Innovation #Pharma #ALLTreatment #CAR_TTherapy #TargetedTherapies

Ibrutinib: another string to its bow. Ibrutinib, the highly potent and irreversible Bruton tyrosine kinase (BTK) inhibitor, has been a game-changer in the treatment of several B-cell malignancies. Since its arrival in 2007, it has demonstrated profound antitumor activity and transformed clinical outcomes for patients with chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrӧm’s macroglobulinemia. Now, a recent study by Rogers and colleagues has shown that the clinical utility of ibrutinib can be expanded even further to hairy cell leukemia (HCL). This is exciting news for patients and healthcare professionals alike. Read the full study here: https://lnkd.in/d4kCTXUe

Asia Pacific Zanubrutinib market was valued at USD 61.30 million and is estimated to reach a value of USD 243 million by 2030 with a CAGR of 21.1% during the forecast period.   The Asia-Pacific Zanubrutinib market is poised for significant growth due to increasing cases of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Countries like China and Japan are driving this demand, with supportive regulatory approvals and heightened investment in oncology treatments. The region's adoption of next-generation Bruton’s tyrosine kinase (BTK) inhibitors like Zanubrutinib is accelerated by its favorable safety profile and efficacy over first-generation drugs like ibrutinib. https://lnkd.in/dKNW-yDs For more details visit: https://lnkd.in/dUfDCYRQ #Zanubrutinib #Brukinsa #AsiaPacificOncology #BTKinhibitors #HematologicalCancers #CLL #MCL #WaldenströmMacroglobulinemia #CancerTreatment #TargetedTherapies #OncologyMarket #AsiaPacificPharma #HematologyDrugs #NextGenBTKInhibitors #CancerInnovation #HealthcareGrowth #PharmaMarketAsia #OncologyDrugs #BcellMalignancies #CancerCareAsiaPacific

Present Generation TKI versus First and Second Gen TKI in CML Molecularly Targeted Therapy in Cancer was revolutionized by the approval of Imatinib (Gleevec), a Receptor Tyrosine Kinase (RTK) targeting the driver mutation BCR: ABL 1 Tyrosine Kinase, for the treatment of Chronic Myelogenous Leukemia (CML). However, due to the inevitable development of resistance the 2nd gen TKIs were developed. The SOC for CML are the 1st and 2nd gen TKIs. Now the latest is Asciminib also a TKI specifically targeting the ABL myristoyl pocket, which has been evaluated in a Phase 3 trial patients with newly diagnosed CML by comparing to the TKI of Physician's choice. The primary endpoint for the evaluation is interesting: major molecular response (defined as BCR::ABL1 transcript levels ≤0.1% on the International Scale [IS]) at week 48. The % of patients with a major molecular response at week 48 was 66.0% with Asciminib and 57.8% with TKIs in the second-generation TKI stratum (difference, 8.2 percentage points; 95% CI, −5.1 to 21.5). Adverse events of grade 3 or higher and events leading to discontinuation of the trial regimen were less frequent with Asciminib (38.0% and 4.5%, respectively) than with imatinib (44.4% and 11.1%) and second-generation TKIs (54.9% and 9.8%). Whether the molecular responses will translate to overall survival benefit remains to be seen. https://lnkd.in/gpybZURe